Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in DLBCL
NCT04827004Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
anlotinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04827004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827004.